Newly identified prognostic markers may be able to accurately stratify for survival in patients with advanced-stage mycosis fundoides (MF) and Sézary syndrome (SS), according to a recent study that included the largest cohort of this patient population.1
Researchers led by Julia Scarisbrick, MBChBhons, FRCP, MD, of University Hospital Birmingham in the United Kingdom examined staging data of 1,275 patients with advanced MF/SS from 29 international specialist centers, with varying markers measured against overall survival risk.
“Published prognostic studies in MF/SS have been single-center trials,” the authors noted. “Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers.”
Continue Reading
Median overall survival was found to be 63 months, with 2-year survival at 77% and 5-year survival at 52%.
RELATED: Brentuximab Vedotin Active, Well-tolerated in Cutaneous T-Cell Lymphoma
Among the 10 markers that were assessed, 4 of them (stage 4 disease, age over 60 years, large-cell transformation, and increased lactate dehydrogenase) were found to be independent prognostic markers for worse survival.
Upon combining those factors in a prognostic index model, 5-year survival was found to be 68% in low-risk patients, 44% in intermediate patients, and 28% in high-risk patients.
Reference
- Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. [published online ahead of print October 5, 2015]. doi: 10.1200/JCO.2015.61.7142.
